GlassScriptPhysician profile
Yun-Wei Chang
NPI 1255708459
$3,537.34
in general payments reported to CMS, 2019-2025
28 companies · $723 in 2025
The $723 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $749 · 2022: $602 · 2023: $553 · 2024: $909 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,185.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $920.10 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $421.61 | 2021-2025 | |
| Glaxosmithkline, LLC. | $344.08 | 2021-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $297.50 | 2021-2024 | |
| Dexcom, INC. | $246.42 | 2022-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $205.11 | 2022-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $195.05 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $189.43 | 2021-2022 | |
| Lilly USA, LLC | $129.69 | 2021-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $88.31 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $66.15 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.99 | 2025 | Caplyta |
| Amgen INC. | $46.51 | 2022-2025 | Repatha, Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $42.35 | 2021-2022 | |
| Esperion Therapeutics, INC. | $40.11 | 2021-2024 | Nexletol |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $32.29 | 2024-2025 | Gemtesa |
| Lundbeck LLC | $29.30 | 2025 | Rexulti |
| Shield Therapeutics INC | $24.16 | 2025 | |
| Jazz Pharmaceuticals INC. | $23.08 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.95 | 2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $21.37 | 2025 | Austedo Xr |
| Biosense Webster, INC. | $18.02 | 2025 | Carto 3 |
| Azurity Pharmaceuticals, INC. | $16.70 | 2024 | |
| Eisai INC. | $15.72 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.66 | 2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $14.97 | 2024 | Trintellix |
| Merck Sharp & Dohme LLC | $12.05 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yun-Wei Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.